T-cell surface glycoprotein CD3 — Drug Target

All drugs that target T-cell surface glycoprotein CD3 — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

CD3-directed Antibody [EPC] · Bispecific CD20-directed CD3 T Cell Engager [EPC] · CD3 Blocker Immunosuppressant

Marketed (5)

• Talvey · Janssen Biotech · Oncology
  Talquetamab binds to the T-cell surface glycoprotein CD3, triggering a response that kills cancer cells.
• TZIELD · PROVENTION BIO INC · CD3-directed Antibody [EPC] · Metabolic
• Tzield · Provention Bio Inc · CD3-directed Antibody [EPC] · Metabolic
  Tzield works by binding to the CD3 complex on T-cells, preventing them from attacking pancreatic beta cells.
• Epkinly · Genmab Us, Inc. · Bispecific CD20-directed CD3 T Cell Engager [EPC] · Oncology
  Epkinly works by binding to the T-cell surface glycoprotein CD3, which is a key component of the T-cell receptor complex.
• Orthoclone Okt3 · Ortho Biotech · CD3 Blocker Immunosuppressant · Immunology

Phase 2 pipeline (1)

• Muromonab · St. Jude Children's Research Hospital · Metabolic